Key result
BVS implantation in STEMI patients shows an ~12% major event rate over two years.
Why the study?
Early clinical results after bioresorbable vascular scaffold implantation in STEMI patients are encouraging, but long-term outcome data are missing.
What are the long-term clinical and imaging outcomes after bioresorbable vascular scaffold implantation in STEMI patients?
Cohort (n=117)
What are the long-term clinical and imaging outcomes after bioresorbable vascular scaffold implantation in STEMI patients?
Bioresorbable vascular scaffold implantation in STEMI patients shows encouraging long-term clinical outcomes with low rates of target vessel revascularization and no late scaffold thrombosis up to 3 years.
Long-term BVS results in selected STEMI patients appear reassuring; leaves open broader applicability pending randomized trials.
AIMS: Early clinical results after implantation of bioresorbable vascular scaffolds (BVS) in ST-elevation myocardial infarction (STEMI) are encouraging, but long-term data are missing. This study evaluates long-term outcome in STEMI patients with implanted BVS. METHODS AND RESULTS: The PRAGUE-19 study is an academic study enrolling consecutive STEMI patients with the intention to implant BVS. A total of 580 STEMI patients were screened between December 2012 and March 2015; 117 patients fulfilled entry criteria and BVS was successfully implanted in 114 (97%) of them. The primary combined clinical endpoint (death, reinfarction or target vessel revascularisation) occurred in 11.5% during the mean follow-up period of 730±275 days with overall mortality of 4.4%. Definite scaffold thrombosis occurred in two patients in the early phase after BVS implantation; there was no late thrombosis. Quantitative coronary angiography (10 patients) at three years demonstrated late lumen loss of 0.2±0.33 mm and optical coherence tomography showed minimal lumen area of 5.3±1.37 mm2 and neointimal hyperplasia area of 2.9±0.48 mm2. BVS struts were still visible at three years and 99.4% of them were well apposed and covered. CONCLUSIONS: Encouraging clinical and imaging results after BVS implantation in STEMI patients persist during long-term follow-up.
No takes yet. Share an insight, caveat, or question.
Toušek et al. (2016) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=117). Bioresorbable vascular scaffolds (BVS) was evaluated on death, reinfarction or target vessel revascularisation. Bioresorbable vascular scaffold implantation in STEMI patients resulted in an 11.5% rate of death, reinfarction, or target vessel revascularization over a mean follow-up of 730 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: